Skip to main content
Polaris AI Pharma Corp. logo

Polaris AI Pharma Corp. — Investor Relations & Filings

Ticker · 041910 ISIN · KR7041910001 KO Manufacturing
Open in API
Filings indexed 164 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 041910

About Polaris AI Pharma Corp.

https://polarisaipharma.com/

Polaris AI Pharma Corp., formerly known as ESTECHPHARMA CO., LTD, is a company engaged in the development, manufacture, and supply of active pharmaceutical ingredients (APIs) and fine chemicals. The company specializes in producing raw materials for generic drugs across various therapeutic categories. Its product portfolio includes APIs for treatments such as anti-thrombosis, anti-ulcer, asthma, and alcohol dependence.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 94% confidence The document is titled “분기보고서” (quarterly report) for the period January 1, 2026 to March 31, 2026 (28th fiscal period). It contains a full table of contents including company overview, business description, detailed financial statements and notes, management discussion and analysis, audit opinion, board and shareholder information, subsidiaries and related party transactions, and other substantive financial disclosures. This matches the definition of an Interim/Quarterly Report rather than a brief announcement or presentation. Q1 2026
2026-05-15 Korean
소속부변경
Regulatory Filings Classification · 95% confidence The document text indicates a change in the company's classification or department within an exchange or regulatory framework, specifically a change from '중견기업부' (mid-sized enterprise division) to '우량기업부' (excellent enterprise division). This is a regulatory announcement about the company's status or classification change, not a financial report, management change, or other specific filing. The document is very short (240 characters) and does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2026-04-30 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 87% confidence The document is a “주요사항보고서(전환사채권 발행결정)” (Key Matters Report for decision to issue convertible bonds) and contains full details on a new convertible bond issuance (amount, terms, conversion period, interest, put/call options, etc.) with an amendment notice to a previously filed report. This is a corporate financing announcement describing a debt‐convertible instrument issuance (i.e., a financing activity and capital structure change). Therefore, it falls under “Capital/Financing Update” (CAP).
2026-03-26 Korean
증권발행결과(자율공시)
Capital/Financing Update Classification · 88% confidence The document is a voluntary disclosure by Polaris AI Pharma detailing the results of its recent securities issuance – specifically a private placement of convertible bonds with the issuance amount, resolution dates, payment date, and listing status. This is clearly an update on the company’s financing activity (fundraising via convertible bonds). It is not a full financial report, AGM material, nor a regulatory notice of vote or delisting. It belongs in the Capital/Financing Update category.
2026-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 92% confidence The document is a formal notification to the Financial Services Commission/Korea Exchange regarding the appointment, reappointment, dismissal, or mid-term resignation of an outside director. It details board composition before and after the change and provides personal data of the newly appointed non-executive director. This clearly falls under announcements of changes in the company's board of directors or senior management. Therefore it is classified as Board/Management Information (MANG).
2026-03-24 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document text is the official results of an ordinary general shareholders’ meeting (정기주주총회결과), including the vote outcomes for each agenda item (e.g., director appointments, remuneration limits). This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA). No broader financial statements are provided beyond summary figures linked to approval votes, and it is clearly the formal vote results rather than a full annual report or proxy statement.
2026-03-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.